{"id":"NCT01407575","sponsor":"University of Pittsburgh","briefTitle":"Buprenorphine for Treatment Resistant Depression","officialTitle":"Buprenorphine For Treatment Resistant Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2011-08-02","resultsPosted":"2016-03-17","lastUpdate":"2018-03-09"},"enrollment":13,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Depression","Depressive Disorder","Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Buprenorphine","otherNames":["suboxone","buprenex","temgesic","subutex"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Buprenorphine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).","primaryOutcome":{"measure":"Montgomery Asberg Depression Rating Scale","timeFrame":"6 weeks","effectByArm":[{"arm":"Buprenorphine","deltaMin":33.8,"sd":10.96},{"arm":"Placebo","deltaMin":32.6,"sd":2.07}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":19},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":[]}}